The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
These re-agent and diagnostic test kits come with 99.7% accuracy
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Submission to be reviewed under FDA real-time oncology review and Project Orbis
Tritan Renew, which is made with 50% certified recycled content derived from hard-to-recycle waste, performs like virgin-quality material
Pivotal trial found the enfortumab vedotin plus pembrolizumab combination significantly extended overall and progression-free survival
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
The new campus has been designed as an employee-centred experience and ecosystem zone
Subscribe To Our Newsletter & Stay Updated
